Paweł Syska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Paweł Syska has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Hanna Szwed
On behalf of the STICH-Family: cardiologists and cardiac surgeons forming the STICH trial team in Poland
5 shared publications - Maciej Sterliński
1st Department of Arrhythmia, National Institute of Cardiology, 04-628 Warsaw, Poland
5 shared publications - Andrzej Przybylski
Faculty of Medicine, University of Rzeszów, Poland
4 shared publications Ilona Kowalik
4 shared publications- Michał Lewandowski
2nd Department of Arrhythmia, National Institute of Cardiology, 04-628 Warsaw, Poland
4 shared publications - Aleksander Maciag
2nd Coronary Disease Depar tment, Institute of Car diology, Warsaw, Poland.
3 shared publications
Latest Publications
- Open Access
- 14 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (18) , 7128
Predictors of Appropriate Implantable Cardioverter-Defibrillator Intervention in Adults with Congenital Heart Disease
Background: Evidence to guide risk stratification after ICD implantation in adults with congenital heart disease (ACHD) is limited. We sought predictors of appropriate ICD intervention in this population. Methods: Consecutive ACHD patients implanted with an ICD (2009–2023) were analysed retrospectively. Time to first appropriate ICD intervention was modelled from a single, consistently defined start of observation. Because only 24 events were available, candidate predictors were pre-specified and each model limited to two covariates; sparse predictors used Firth penalisation, and multiplicity was addressed by the Benjamini–Hochberg false discovery rate procedure. Results: Among 56 patients (73.2% male; 22 primary and 34 secondary prevention), appropriate intervention occurred in 24 (42.9%) over a median follow-up of 51.9 months. Atrial fibrillation (HR 2.75, 95% CI 1.22–6.23) and radiographic cardiomegaly (HR 3.99, 95% CI 1.28–12.40) showed the largest unadjusted associations, whereas individual congenital lesions and disease-severity descriptors did not. No predictor remained significant after Benjamini–Hochberg correction (q ≈ 0.10). The very high hazard ratios for sparsely represented thyroid disorders (hypothyroidism, n = 2; hyperthyroidism, n = 4) were unstable under penalised estimation and are reported as exploratory. A pre-specified two-variable model (atrial fibrillation plus radiographic cardiomegaly) showed modest discrimination (optimism-corrected Harrell’s C-index 0.63). Conclusions: In a heterogeneous real-world ACHD cohort, a history of atrial fibrillation and radiographic cardiomegaly were associated with appropriate ICD intervention. Given the small number of events and the sparsity of several predictors, these findings should be regarded as hypothesis-generating and require validation in larger multicentre ACHD cohorts.
- 14 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (18) , 7128
Open AccessPredictors of Appropriate Implantable Cardioverter-Defibrillator Intervention in Adults with Congenital Heart Disease
Background: Evidence to guide risk stratification after ICD implantation in adults with congenital heart disease (ACHD) is limited. We sought predictors of appropriate ICD intervention in this population. Methods: Consecutive ACHD patients implanted with an ICD (2009–2023) were analysed retrospectively. Time to first appropriate ICD intervention was modelled from a single, consistently defined start of observation. Because only 24 events were available, candidate predictors were pre-specified and each model limited to two covariates; sparse predictors used Firth penalisation, and multiplicity was addressed by the Benjamini–Hochberg false discovery rate procedure. Results: Among 56 patients (73.2% male; 22 primary and 34 secondary prevention), appropriate intervention occurred in 24 (42.9%) over a median follow-up of 51.9 months. Atrial fibrillation (HR 2.75, 95% CI 1.22–6.23) and radiographic cardiomegaly (HR 3.99, 95% CI 1.28–12.40) showed the largest unadjusted associations, whereas individual congenital lesions and disease-severity descriptors did not. No predictor remained significant after Benjamini–Hochberg correction (q ≈ 0.10). The very high hazard ratios for sparsely represented thyroid disorders (hypothyroidism, n = 2; hyperthyroidism, n = 4) were unstable under penalised estimation and are reported as exploratory. A pre-specified two-variable model (atrial fibrillation plus radiographic cardiomegaly) showed modest discrimination (optimism-corrected Harrell’s C-index 0.63). Conclusions: In a heterogeneous real-world ACHD cohort, a history of atrial fibrillation and radiographic cardiomegaly were associated with appropriate ICD intervention. Given the small number of events and the sparsity of several predictors, these findings should be regarded as hypothesis-generating and require validation in larger multicentre ACHD cohorts.
- 11 April 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (5) , 1043-1047
Extravascular Cardioverter‐Defibrillator for Primary Prevention in an 11‐Year‐Old Boy With Phenotype of High Risk Overlapping Cardiomyopathies
Background: The extravascular implantable cardioverter‐defibrillator (EV‐ICD; Aurora™, Medtronic) is a novel non‐transvenous system introduced in 2023. While its safety and efficacy have been demonstrated in adults, experience in pediatric patients remains limited despite potential advantages in this population. Case Presentation: We report an 11‐year‐old boy with complex cardiomyopathy (hypertrophic, dilated, and noncompaction) and high risk of sudden cardiac death (HCM Risk‐Kids score 15.6%). Due to the absence of pacing indications and unsuccessful subcutaneous ICD screening, an EV‐ICD was selected. The device was implanted via a minimally invasive retrosternal approach without complications. Excellent sensing and pacing parameters were achieved, and the patient was discharged in good condition. Results: The implantation was feasible and safe, with stable electrical parameters and no perioperative complications. The close proximity of the substernal lead to the myocardium likely contributed to favorable device performance. Conclusion: EV‐ICD implantation may be a viable alternative to transvenous systems in selected pediatric patients. Further studies and long‐term follow‐up are required to evaluate device performance during growth and development.
- 11 April 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (5) , 1043-1047
Extravascular Cardioverter‐Defibrillator for Primary Prevention in an 11‐Year‐Old Boy With Phenotype of High Risk Overlapping Cardiomyopathies
Background: The extravascular implantable cardioverter‐defibrillator (EV‐ICD; Aurora™, Medtronic) is a novel non‐transvenous system introduced in 2023. While its safety and efficacy have been demonstrated in adults, experience in pediatric patients remains limited despite potential advantages in this population. Case Presentation: We report an 11‐year‐old boy with complex cardiomyopathy (hypertrophic, dilated, and noncompaction) and high risk of sudden cardiac death (HCM Risk‐Kids score 15.6%). Due to the absence of pacing indications and unsuccessful subcutaneous ICD screening, an EV‐ICD was selected. The device was implanted via a minimally invasive retrosternal approach without complications. Excellent sensing and pacing parameters were achieved, and the patient was discharged in good condition. Results: The implantation was feasible and safe, with stable electrical parameters and no perioperative complications. The close proximity of the substernal lead to the myocardium likely contributed to favorable device performance. Conclusion: EV‐ICD implantation may be a viable alternative to transvenous systems in selected pediatric patients. Further studies and long‐term follow‐up are required to evaluate device performance during growth and development.
- Open Access
- 19 April 2023
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 32 (11) , 1249-1256
Employment of the Evolution RL sheath as a first-choice device shortens transvenous lead extraction time without affecting procedural safety and efficacy compared to its auxiliary use: Insights from the prospective multicenter EVO registry
Background. Transvenous lead extraction (TLE) is recommended in cases of local and systemic infections related to cardiac implantable electronic devices (CIEDs). Additionally, TLE is indicated in the event of lead damage or CIED malfunction. The extraction procedure is associated with a risk of life-threatening complications. Objectives. The aim of the EVO registry was to assess the safety and efficacy of birotational Evolution tool usage. Materials and methods. This registry study was prospectively conducted in 8 high-volume implantation centers in Poland. The study included 133 patients aged 63.5 +/- 15.1 years, and 76.69% were male. Indications for the procedure were: local or systemic infection (33.1%) and lead dysfunction (66.9%). The number of leads extracted varied from 1 (39.84%) to 3 (9.77%). Results. Clinical procedural success was achieved in 99.1% of cases. A total of 226 leads were extracted, and 206 used the Evolution system. Two procedural strategies were identified while using the Evolution system: (1) usage of locking stylet, propylene sheaths and the Evolution system (118 leads, 52%) - group A; (2) usage of locking styletand Evolution (88 leads, 39%) - group B. There were no differences in the number of complications between these 2 groups. The extraction time was significantly shorter (p = 0.02) in group B than in group A. Major complications occurred in 5.2% of cases with 2 intraprocedural deaths. Minor complications occurred in 1.5% of patients. Conclusions. The registry confirmed the efficacy and relative safety of the birotational Evolution sheath. Using the rotational sheath as a first attempt significantly reduces extraction time without compromising its safety.
- 19 April 2023
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 32 (11) , 1249-1256
Open AccessEmployment of the Evolution RL sheath as a first-choice device shortens transvenous lead extraction time without affecting procedural safety and efficacy compared to its auxiliary use: Insights from the prospective multicenter EVO registry
Background. Transvenous lead extraction (TLE) is recommended in cases of local and systemic infections related to cardiac implantable electronic devices (CIEDs). Additionally, TLE is indicated in the event of lead damage or CIED malfunction. The extraction procedure is associated with a risk of life-threatening complications. Objectives. The aim of the EVO registry was to assess the safety and efficacy of birotational Evolution tool usage. Materials and methods. This registry study was prospectively conducted in 8 high-volume implantation centers in Poland. The study included 133 patients aged 63.5 +/- 15.1 years, and 76.69% were male. Indications for the procedure were: local or systemic infection (33.1%) and lead dysfunction (66.9%). The number of leads extracted varied from 1 (39.84%) to 3 (9.77%). Results. Clinical procedural success was achieved in 99.1% of cases. A total of 226 leads were extracted, and 206 used the Evolution system. Two procedural strategies were identified while using the Evolution system: (1) usage of locking stylet, propylene sheaths and the Evolution system (118 leads, 52%) - group A; (2) usage of locking styletand Evolution (88 leads, 39%) - group B. There were no differences in the number of complications between these 2 groups. The extraction time was significantly shorter (p = 0.02) in group B than in group A. Major complications occurred in 5.2% of cases with 2 intraprocedural deaths. Minor complications occurred in 1.5% of patients. Conclusions. The registry confirmed the efficacy and relative safety of the birotational Evolution sheath. Using the rotational sheath as a first attempt significantly reduces extraction time without compromising its safety.
- Open Access
- 27 June 2020
- Published by MDPI AG in Diagnostics
- Vol. 10 (7) , 435
A Recurrent Exertional Syncope and Sudden Cardiac Arrest in a Young Athlete with Known Pathogenic p.Arg420Gln Variant in the RYR2 Gene
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is one of causes of sudden cardiac death in the young, especially in athletes. Diagnosis of CPVT may be difficult since all cardiological examinations performed at rest are usually normal, and exercise stress test-induced ventricular tachycardia is not commonly present. The identification of a pathogenic mutation in RYR2 or CASQ2 is diagnostic in CPVT. We report on a 20-year-old athlete who survived two sudden cardiac arrests during swimming. Moreover, he suffered repeated syncopal spells on exercise. The diagnosis was made only following genetic testing using a multi-gene panel, and the p.Arg420Gln RYR2 variant was identified. We present diagnostic and therapeutic issues in this young athlete with CPVT.
- 27 June 2020
- Published by MDPI AG in Diagnostics
- Vol. 10 (7) , 435
Open AccessA Recurrent Exertional Syncope and Sudden Cardiac Arrest in a Young Athlete with Known Pathogenic p.Arg420Gln Variant in the RYR2 Gene
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is one of causes of sudden cardiac death in the young, especially in athletes. Diagnosis of CPVT may be difficult since all cardiological examinations performed at rest are usually normal, and exercise stress test-induced ventricular tachycardia is not commonly present. The identification of a pathogenic mutation in RYR2 or CASQ2 is diagnostic in CPVT. We report on a 20-year-old athlete who survived two sudden cardiac arrests during swimming. Moreover, he suffered repeated syncopal spells on exercise. The diagnosis was made only following genetic testing using a multi-gene panel, and the p.Arg420Gln RYR2 variant was identified. We present diagnostic and therapeutic issues in this young athlete with CPVT.
- Open Access
- 12 May 2020
- Published by Springer Nature in Trials
- Vol. 21 (1) , 1-7
Clinical efficacy of potassium canreonate-canrenone in sinus rhythm restoration among patients with atrial fibrillation - a protocol of a pilot, randomized, double -blind, placebo-controlled study (CANREN-AF trial)
Background: Atrial fibrillation (AF) is the most frequent cardiac arrhythmia which increases the risk of thromboembolic complications and impairs quality of life. An important part of a therapeutic approach for AF is sinus rhythm restoration. Antiarrhythmic agents used in pharmacological cardioversion have limited efficacy and potential risk of proarrhythmia. Simultaneously, underlying conditions of AF should be treated (e.g. electrolyte imbalance, increased blood pressure, neurohormonal disturbances, atrial volume overload). There is still the need for an effective and safe approach to increase AF cardioversion efficacy. This randomized, double-blind, placebo-controlled, superiority clinical study is performed in patients with AF in order to evaluate the clinical efficacy of intravenous canrenone in sinus rhythm restoration. Methods: Eighty eligible patients with an episode of AF lasting less than 48 h are randomized in a 1:1 ratio to receive canrenone or placebo. Patients randomized to a treatment intervention are receiving canrenone intravenously at a dose of 200 mg within 2–3 min. Subjects assigned to a control group obtain the same volume of 0.9% saline within the same time. The primary endpoint includes return of sinus rhythm documented in the electrocardiogram within 2 h after drug or placebo administration. Other endpoints and safety outcomes analyses, due to expected lack of statistical power, are exploratory. Discussion: Current evidence supports renin–angiotensin–aldosterone system (RAAS) inhibition as an upstream therapy in AF management. Excess aldosterone secretion results in proarrhythmic effects. Among the RAAS inhibitors, only canrenone is administered intravenously. Canrenone additionally increases the plasma level of potassium, lowers blood pressure and reduces preload. It has been already used in primary and secondary hyperaldosteronism in the course of chronic liver dysfunction and in heart failure. Trial registration: ClinicalTrials.gov, NCT03536806. Registered on 25 May 2018.
- 12 May 2020
- Published by Springer Nature in Trials
- Vol. 21 (1) , 1-7
Open AccessClinical efficacy of potassium canreonate-canrenone in sinus rhythm restoration among patients with atrial fibrillation - a protocol of a pilot, randomized, double -blind, placebo-controlled study (CANREN-AF trial)
Background: Atrial fibrillation (AF) is the most frequent cardiac arrhythmia which increases the risk of thromboembolic complications and impairs quality of life. An important part of a therapeutic approach for AF is sinus rhythm restoration. Antiarrhythmic agents used in pharmacological cardioversion have limited efficacy and potential risk of proarrhythmia. Simultaneously, underlying conditions of AF should be treated (e.g. electrolyte imbalance, increased blood pressure, neurohormonal disturbances, atrial volume overload). There is still the need for an effective and safe approach to increase AF cardioversion efficacy. This randomized, double-blind, placebo-controlled, superiority clinical study is performed in patients with AF in order to evaluate the clinical efficacy of intravenous canrenone in sinus rhythm restoration. Methods: Eighty eligible patients with an episode of AF lasting less than 48 h are randomized in a 1:1 ratio to receive canrenone or placebo. Patients randomized to a treatment intervention are receiving canrenone intravenously at a dose of 200 mg within 2–3 min. Subjects assigned to a control group obtain the same volume of 0.9% saline within the same time. The primary endpoint includes return of sinus rhythm documented in the electrocardiogram within 2 h after drug or placebo administration. Other endpoints and safety outcomes analyses, due to expected lack of statistical power, are exploratory. Discussion: Current evidence supports renin–angiotensin–aldosterone system (RAAS) inhibition as an upstream therapy in AF management. Excess aldosterone secretion results in proarrhythmic effects. Among the RAAS inhibitors, only canrenone is administered intravenously. Canrenone additionally increases the plasma level of potassium, lowers blood pressure and reduces preload. It has been already used in primary and secondary hyperaldosteronism in the course of chronic liver dysfunction and in heart failure. Trial registration: ClinicalTrials.gov, NCT03536806. Registered on 25 May 2018.
- 30 April 2020
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 31 (6) , 1470-1471
Cephalic access with multiple leads may increase the risk of early ICD lead failure. Time to question the dogma?
Despite extreme and undeniable progress in the concept of implantable cardioverter defibrillator (ICD) therapy over the last 40 years, the endocardial lead is still the weakest link of the system. Many efforts have been taken to improve the construction and consequently the durability of the lead. Not all of them were successful and some of the lead models proved to be technically imperfect, resulting in formal recalls. Similarly, patient‐ and procedure‐related factors may strongly affect the lead reliability.
- 30 April 2020
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 31 (6) , 1470-1471
Cephalic access with multiple leads may increase the risk of early ICD lead failure. Time to question the dogma?
Despite extreme and undeniable progress in the concept of implantable cardioverter defibrillator (ICD) therapy over the last 40 years, the endocardial lead is still the weakest link of the system. Many efforts have been taken to improve the construction and consequently the durability of the lead. Not all of them were successful and some of the lead models proved to be technically imperfect, resulting in formal recalls. Similarly, patient‐ and procedure‐related factors may strongly affect the lead reliability.
- Open Access
- 20 June 2017
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 19 (suppl_3) , iii293
P1451Clinical and pacing parameters related to atrial fibrillation in patients with tachycardia-bradycardia syndrome
Background: There is some evidence about the factors related to the development of atrial fibrillation (AF) in patients with sinus node disease but the influence of those parameters in the subgroup of tachycardia bradycardia syndrome (TBS) patients remains unclear. There is no data examining the impact of different RVp% profiles on AF development those patients.
- 20 June 2017
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 19 (suppl_3) , iii293
Open AccessP1451Clinical and pacing parameters related to atrial fibrillation in patients with tachycardia-bradycardia syndrome
Background: There is some evidence about the factors related to the development of atrial fibrillation (AF) in patients with sinus node disease but the influence of those parameters in the subgroup of tachycardia bradycardia syndrome (TBS) patients remains unclear. There is no data examining the impact of different RVp% profiles on AF development those patients.
- Open Access
- 4 October 2014
- Published by Springer Nature in Trials
- Vol. 15 (1) , 1-9
Comparison of the rhythm control treatment strategy versus the rate control strategy in patients with permanent or long-standing persistent atrial fibrillation and heart failure treated with cardiac resynchronization therapy - a pilot study of Cardiac Resynchronization in Atrial Fibrillation Trial (Pilot-CRAfT): study protocol for a randomized controlled trial
The only subgroups of patients with heart failure and atrial fibrillation in which the efficacy of cardiac resynchronization therapy has been scientifically proven are patients with indications for right ventricular pacing and patients after atrioventricular junction ablation. However it is unlikely that atrioventricular junction ablation would be a standard procedure in the majority of the heart failure patients with cardiac resynchronization therapy and concomitant atrial fibrillation due to the irreversible character of the procedure and a spontaneous sinus rhythm resumption that occurs in about 10% of these patients. Pilot-CRAfT is the first randomized controlled trial evaluating the efficacy of a rhythm control strategy in atrial fibrillation patients with cardiac resynchronization therapy devices. The aim of this prospective, single center randomized controlled pilot study is to answer the question whether the patients with cardiac resynchronization therapy and permanent atrial fibrillation would benefit from a strategy to restore and maintain sinus rhythm (that is ‘rhythm control’ strategy) in comparison to rate control strategy. The study population consists of 60 patients with heart failure and concomitant long-standing persistent or permanent atrial fibrillation who underwent a cardiac resynchronization therapy device implantation at least 3 months before qualification. Study participants are randomly assigned to the rhythm control strategy (including electrical cardioversion and pharmacotherapy) or to the rate control group whose goal is to control ventricular rate. The follow-up time is 12 months. The primary endpoint is the ratio of effectively captured biventricular beats. The secondary endpoints include peak oxygen consumption, six-minute walk test distance, heart failure symptom escalation, reverse remodelling of the heart on echo and quality of life. NCT01850277 registered on 22 April 2013 (ClinicalTrails.gov)
- 4 October 2014
- Published by Springer Nature in Trials
- Vol. 15 (1) , 1-9
Open AccessComparison of the rhythm control treatment strategy versus the rate control strategy in patients with permanent or long-standing persistent atrial fibrillation and heart failure treated with cardiac resynchronization therapy - a pilot study of Cardiac Resynchronization in Atrial Fibrillation Trial (Pilot-CRAfT): study protocol for a randomized controlled trial
The only subgroups of patients with heart failure and atrial fibrillation in which the efficacy of cardiac resynchronization therapy has been scientifically proven are patients with indications for right ventricular pacing and patients after atrioventricular junction ablation. However it is unlikely that atrioventricular junction ablation would be a standard procedure in the majority of the heart failure patients with cardiac resynchronization therapy and concomitant atrial fibrillation due to the irreversible character of the procedure and a spontaneous sinus rhythm resumption that occurs in about 10% of these patients. Pilot-CRAfT is the first randomized controlled trial evaluating the efficacy of a rhythm control strategy in atrial fibrillation patients with cardiac resynchronization therapy devices. The aim of this prospective, single center randomized controlled pilot study is to answer the question whether the patients with cardiac resynchronization therapy and permanent atrial fibrillation would benefit from a strategy to restore and maintain sinus rhythm (that is ‘rhythm control’ strategy) in comparison to rate control strategy. The study population consists of 60 patients with heart failure and concomitant long-standing persistent or permanent atrial fibrillation who underwent a cardiac resynchronization therapy device implantation at least 3 months before qualification. Study participants are randomly assigned to the rhythm control strategy (including electrical cardioversion and pharmacotherapy) or to the rate control group whose goal is to control ventricular rate. The follow-up time is 12 months. The primary endpoint is the ratio of effectively captured biventricular beats. The secondary endpoints include peak oxygen consumption, six-minute walk test distance, heart failure symptom escalation, reverse remodelling of the heart on echo and quality of life. NCT01850277 registered on 22 April 2013 (ClinicalTrails.gov)
- 1 September 2010
- Vol. 68 (9) , 1023-9
Over 10 years with an implantable cardioverter-defibrillator - a long term follow-up of 60 patients.
Transvenous implantable cardioverter-defibrillators (ICD) have been implanted in Poland since 1995. As the method spreads it is important to consider its long-term benefits and disadvantages. To assess survival, efficacy and complication rate in ICD patients, who received the device more than ten years earlier. Retrospective analysis of 60 ICD patients implanted between 1995-1999. There were 42 (70%) males, mean age 50.6 ± 16.4 years. In 59 patients ICD was implanted for sudden cardiac death (SCD) secondary prevention. Thirty eight patients (34 M, 63.3%) had coronary artery disease (CAD). The CAD was diagnosed in 89.5% of males and 10.5% of females (p〈 0.0001). Mean follow-up time was 75.4 ± 34.7 months. During this time 22 patients died (37%, 19 M, 3 F). Three deaths were SCD. Mean one-year mortality was 6.7%. Deaths were more frequent among males: 45.2% vs 16.7%, p〈 0.005. In CAD mortality was higher than in non-CAD patients (50% vs 13.6%, p〈 0.005). Appropriate ICD discharges in the ventricular fibrillation (VF) zone occurred in 35 (58%) patients, and in ventricular tachycardia (VT) zone - in 26 (43%) patients. Mean intervention rate per year was 3.7 for VF and 0.6 for VT. Complications occurred in 27 (45%) patients and 5 (8%) of them had no ICD intervention during follow-up. In 5 patients more than one complication was diagnosed. There were inappropriate discharges in 15 (25%) patients, 11 (18%) had electrical storm, and ICD-related infections were noted in 3 (5%) patients. During the perioperative period, lead revisions were done in 4 patients; in 3 with discharges induced by T-wave oversensing and in one with lead dislocation. Four cases of lead failure occurred during follow-up, requiring new lead implantation. In 4 patients, electrical storm (3 patients) and supraventricular tachycardia with ICD discharges (1 patient) were treated with radiofrequency ablation. Only 10 (17%) patients did not demonstrate any ICD interventions or ICD-related complications. 1. ICD interventions caused by malignant ventricular arrhythmias occurred in 75% patients with the device implanted more than 10 years earlier. 2. Almost a half of the analysed population suffered from complications and side effects related to implanted ICD and they were present in 8% of subjects without ICD intervention. Neither ICD interventions nor device-related adverse events were recorded in 17% of patients.
- 1 September 2010
- Vol. 68 (9) , 1023-9
Over 10 years with an implantable cardioverter-defibrillator - a long term follow-up of 60 patients.
Transvenous implantable cardioverter-defibrillators (ICD) have been implanted in Poland since 1995. As the method spreads it is important to consider its long-term benefits and disadvantages. To assess survival, efficacy and complication rate in ICD patients, who received the device more than ten years earlier. Retrospective analysis of 60 ICD patients implanted between 1995-1999. There were 42 (70%) males, mean age 50.6 ± 16.4 years. In 59 patients ICD was implanted for sudden cardiac death (SCD) secondary prevention. Thirty eight patients (34 M, 63.3%) had coronary artery disease (CAD). The CAD was diagnosed in 89.5% of males and 10.5% of females (p〈 0.0001). Mean follow-up time was 75.4 ± 34.7 months. During this time 22 patients died (37%, 19 M, 3 F). Three deaths were SCD. Mean one-year mortality was 6.7%. Deaths were more frequent among males: 45.2% vs 16.7%, p〈 0.005. In CAD mortality was higher than in non-CAD patients (50% vs 13.6%, p〈 0.005). Appropriate ICD discharges in the ventricular fibrillation (VF) zone occurred in 35 (58%) patients, and in ventricular tachycardia (VT) zone - in 26 (43%) patients. Mean intervention rate per year was 3.7 for VF and 0.6 for VT. Complications occurred in 27 (45%) patients and 5 (8%) of them had no ICD intervention during follow-up. In 5 patients more than one complication was diagnosed. There were inappropriate discharges in 15 (25%) patients, 11 (18%) had electrical storm, and ICD-related infections were noted in 3 (5%) patients. During the perioperative period, lead revisions were done in 4 patients; in 3 with discharges induced by T-wave oversensing and in one with lead dislocation. Four cases of lead failure occurred during follow-up, requiring new lead implantation. In 4 patients, electrical storm (3 patients) and supraventricular tachycardia with ICD discharges (1 patient) were treated with radiofrequency ablation. Only 10 (17%) patients did not demonstrate any ICD interventions or ICD-related complications. 1. ICD interventions caused by malignant ventricular arrhythmias occurred in 75% patients with the device implanted more than 10 years earlier. 2. Almost a half of the analysed population suffered from complications and side effects related to implanted ICD and they were present in 8% of subjects without ICD intervention. Neither ICD interventions nor device-related adverse events were recorded in 17% of patients.
- 3 August 2010
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 21 (8) , 883-889
Implantable Cardioverter‐Defibrillator in Patients With Hypertrophic Cardiomyopathy: Efficacy and Complications of the Therapy in Long‐Term Follow‐up
ICD in Hypertrophic Cardiomyopathy Patients. Introduction: Although implantable cardioverter‐defibrillators (ICDs) are used in sudden cardiac death (SCD) prevention in high‐risk patients with hypertrophic cardiomyopathy (HCM), long‐term results as well as precise risk stratification are discussed in a limited number of reports. The aim of the study was to assess the incidence of ICD intervention in HCM patients with relation to clinical risk profile. Methods and Results: We studied 104 consecutive patients with HCM implanted in a single center. The mean age of study population was 35.6 (SD, 16.2) years with the average follow‐up of 4.6 (SD, 2.6) years. ICD was implanted for secondary (n = 26) and primary (n = 78) prevention of SCD. In the secondary prevention group, 14 patients (53.8%) experienced at least 1 appropriate device intervention (7.9%/year). In the primary prevention (PP) group appropriate ICD discharges occurred in 13 patients (16.7%) and intervention rate was 4.0%/year. Nonsustained VT was the only predictive risk factor (RF) for an appropriate ICD intervention in the PP (positive predictive value 22%, negative predictive value 96%). No significant difference was observed in the incidence of appropriate ICD discharges between PP patients with 1, 2, or more RF. Complications of the treatment included: inappropriate shocks (33.7%), lead dysfunction (12.5%), and infections: 4.8% of patients. Four patients died during follow‐up. Conclusion: ICD therapy is effective in SCD prevention in patients with HCM, although the complication rate is significant. Nonsustained ventricular tachycardia seems to be the most predictive RF for appropriate device discharges. Number of RF did not impact the incidence of appropriate ICD interventions. (J Cardiovasc Electrophysiol, Vol. 21, pp. 883‐889, August 2010)
- 3 August 2010
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 21 (8) , 883-889
Implantable Cardioverter‐Defibrillator in Patients With Hypertrophic Cardiomyopathy: Efficacy and Complications of the Therapy in Long‐Term Follow‐up
ICD in Hypertrophic Cardiomyopathy Patients. Introduction: Although implantable cardioverter‐defibrillators (ICDs) are used in sudden cardiac death (SCD) prevention in high‐risk patients with hypertrophic cardiomyopathy (HCM), long‐term results as well as precise risk stratification are discussed in a limited number of reports. The aim of the study was to assess the incidence of ICD intervention in HCM patients with relation to clinical risk profile. Methods and Results: We studied 104 consecutive patients with HCM implanted in a single center. The mean age of study population was 35.6 (SD, 16.2) years with the average follow‐up of 4.6 (SD, 2.6) years. ICD was implanted for secondary (n = 26) and primary (n = 78) prevention of SCD. In the secondary prevention group, 14 patients (53.8%) experienced at least 1 appropriate device intervention (7.9%/year). In the primary prevention (PP) group appropriate ICD discharges occurred in 13 patients (16.7%) and intervention rate was 4.0%/year. Nonsustained VT was the only predictive risk factor (RF) for an appropriate ICD intervention in the PP (positive predictive value 22%, negative predictive value 96%). No significant difference was observed in the incidence of appropriate ICD discharges between PP patients with 1, 2, or more RF. Complications of the treatment included: inappropriate shocks (33.7%), lead dysfunction (12.5%), and infections: 4.8% of patients. Four patients died during follow‐up. Conclusion: ICD therapy is effective in SCD prevention in patients with HCM, although the complication rate is significant. Nonsustained ventricular tachycardia seems to be the most predictive RF for appropriate device discharges. Number of RF did not impact the incidence of appropriate ICD interventions. (J Cardiovasc Electrophysiol, Vol. 21, pp. 883‐889, August 2010)